Патофизиологические механизмы и генетические маркеры рестеноза после чрескожных коронарных вмешательств
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Полный текст:
Аннотация
Рестенозирование коронарных артерий (КА) остается главным ограничением эффективности чрескожной транслюминальной коронарной ангиопластики (ЧТКА) и коронарного стентирования (КС). Цель обзора – рассмотреть механизмы патогенеза рестенозирования КА после ЧТКА и КС; проанализировать различные полиморфизмы кандидатных генов, которые могут быть вовлечены в патогенез развития рестеноза после баллонной ангиопластики (БАП) и рестеноза в стенте, как потенциальные генетические маркеры развития рестеноза после ЧТКА и КС.
Патофизиологические механизмы, генетический базис развития рестеноза в стенте и после БАП без стентирования различаются. Существуют гены, которые могут быть использованы как генетические маркеры риска развития рестеноза в стенте. С другой стороны, есть гены, которые служат генетическими маркерами риска развития рестеноза после ЧТКА. Генетическое тестирование перед выполнением ЧТКА, в ближайшем будущем позволит определять пациентов с высоким риском развития рестеноза, что вместе с разработкой новых фармакологических подходов будет способствовать снижению частоты рестенозирования КА после БАП и КС.
Об авторах
Ю. А. Шувалова
ФГУ «Российский кардиологический научно-производственный комплекс» Росздрава, Москва
Россия
Тел.: (495)414-67-98
Факс: (495)414-67-97
Россия
Тел.: (495)414-67-98
Факс: (495)414-67-97
А. Н. Мешков
ФГУ «Российский кардиологический научно-производственный комплекс» Росздрава, Москва
Россия
Тел.: (495)414-67-98
Факс: (495)414-67-97
Россия
Тел.: (495)414-67-98
Факс: (495)414-67-97
А. И. Каминный
ФГУ «Российский кардиологический научно-производственный комплекс» Росздрава, Москва
Россия
Тел.: (495)414-67-98
Факс: (495)414-67-97
Россия
Тел.: (495)414-67-98
Факс: (495)414-67-97
Г. Ф. Пиксина
ФГУ «Российский кардиологический научно-производственный комплекс» Росздрава, Москва
Россия
Тел.: (495)414-67-98
Факс: (495)414-67-97
Россия
Тел.: (495)414-67-98
Факс: (495)414-67-97
В. В. Кухарчук
ФГУ «Российский кардиологический научно-производственный комплекс» Росздрава, Москва
Россия
Тел.: (495)414-67-98
Факс: (495)414-67-97
Россия
Тел.: (495)414-67-98
Факс: (495)414-67-97
Список литературы
1. Fischman DL, Leon MB, Baim DS, et al. A randomized com- parison of coronary - stene placement and balloon angioplasty in the treatment of cprpnary artery disease. Stent Restenosis Study Investigators. N Engl J Med, 1994; 331: 496-501
2. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of bal- loon - expandable - stent implantation eith balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med, 1994; 331: 489-95
3. Hoffmann R, Mintz GS. Coronary in-stent restenosis - predic- tors, treatment and prevention. Europ Heart J, 2000; 21: 1739-49
4. Schwartz RS, Holmes DR, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. JACC, 1992; 20: 1284-93
5. Horibe H, Yamada Y, Ichihara S, et al. Genetic risk for restenosis after coronary ballon angioplasty. Aterosclerosis, 2004; 174: 181-7
6. Mintz GS, Popma JJ, Pichard AD, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation, 1996; 94: 35-43
7. Agema WRP, Jukema JW, Pimstone SN, Kastelein JJP. Genetic aspects of restenosis after percutaneous coronary interventions. Eur Heart J, 2001; 22: 2058-74
8. DA Lane and PJ Grant. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood, 2000; 95: 1517-32
9. Chandrasekar B, Tanguay J-F. Platele ts and restenosis. JACC, 2000; 35: 555-62
10. Gawaz M, Neumann FJ, Ott I, et al. Changes in membrane gly- coproteins of circulating platelets after coronary stent implanta- tion. Heart. 1996; 76: 166-72
11. Calvette JJ. On the structure and function of platelet integrin a_IIb b_3, the fibrinogen receptor. Proc Soc Exp Biol Med, 1995; 208: 346-60
12. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation, 1999; 99: 44-52
13. Carter AM, Ossei-Gerning N, Wilson IJ, et al. Association of the platelet PlA polymorphism of glycoprotein IIb/IIIa and the fib- rinogen Bβ 448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation, 1997; 96: 1424-31
14. Montalescot G, Ankri A, Vicaut E, et al. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation, 1995; 92: 31-8
15. Sakata K Miura F, Sugino H, et al. Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associat- ed with restenosis. Am Heart J, 1996; 131: 1-6
16. Volzke H, Grimm R, Robinson DM, et al. Candidate genetic markers and the risk of restenosis after coronary angioplasty. Clin Sci (Lond), 2004. 106: 35-42
17. Mamotte CD, van Bockxmeer FM, Taylor RR. Pla1/Pla2 poly- morphism of glycoprotein IIIa and risk of coronary artery disease and restenosis following coronary angioplasty. Am J Cardiol. 1998; 82: 13-6
18. Monraats PS, Rana JS, Zwinderman AH, et al. -455G/A poly- morphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placement. Thromb Haemost, 2005; 93(3): 564-9
19. Kastrati A, Koch W, Gawaz M, et al. PLA polymorphism of gly- coprotein IIIa and risk of adverse events after coronary stent placement. JACC, 2000; 36: 84-9
20. Bottiger C, Koch W, Lahn C, et al. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting. Am Heart J, 2003; 146: 855-61
21. Ortlepp JR, Hoffmann R, Killian A, et al. The 4G/5G promoter polymorphism of the plasninogen activator inhibitor-1 gene and late lumen loss after coronary stent placement in smoking and nonsmoking patients. Clin Cardiol, 2001; 24: 585-91
22. von Beckerath N, Koch W, Mehilli J, et al. Glycoprotein Ia C807T polymorphism and risk of restenosis following coronary stenting. Atherosclerosis, 2001; 156: 463-8
23. Toutouzas K, Colombo A, Stefanadis C. Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J, 2004; 25: 1679-87
24. Tashiro H, Shimokawa H, Sadamatsu K, et al. Role of cytokines in the pathogenesis of restenosis after percutaneous transluminal coronary angioplasty. Coron Artery Dis, 2001; 12: 107-13
25. Francis SE, Camp NJ, Burton AJ, et al. Interleukin 1 receptor antagonist gene polymorphism and restenosis after coronary angioplasty. Heart, 2001; 86: 336-40
26. Kastrati A, Koch W, Berger PB, et al. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. JACC, 2000; 36: 2168-73
27. Gomma AH, Elrayess MA, Knight CJ, et al. The endothelial nitric oxide synthase (Glu298Asp and -786T>C) gene polymorphism are associated with coronary in-stent restenosis. Eur Heart J, 2002; 23: 1955-62
28. Koch W, Tiroch K, von Beckerath N, et al. Tumor necrosis factor-alpha, lymphotoxin-alpha, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting. Cytokine, 2003; 24: 161-71
29. Humphries S, Bauters C, Meirhaeghe A, et al. The 5A6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene as a risk factor for restenosis. Eur Heart J, 2002;23: 721-5
30. Chiou KR, Chung SL, Charng MJ. 5A/6A polymorphism of the stromelysin-1 gene and angiographic restenosis after coronary artery stenting. J Chin Med Assoc, 2005; 68(11): 506-12
31. Hoppmann P, Koch W, Schomig A, Kastrati A. The 5A/6A polymorphism of the stromelysin-1 gene and restenosis after percuta-neous coronary interventions Eur Heart J, 2004; 25: 335-41
32. Itoh H, Mukoyama M, Pratt RE, et al. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest, 1993; 91: 2268-74
33. Oike Y, Hata A, Ogata Y, et al. Angiotensin converting enzyme as a genetic risk factor for coronary artery spasm. Implication in the pathogenesis of myocardial infarction. J Clin Invest, 1995; 96: 2975-9
34. Prisco D, Fatini C, Battaglini B, et al. Angiotensin converting enzyme DD genotype affects the changes of plasma plasminogen activator inhibitor-1 activity after primary percutaneous transluminal coronary angioplasty in acute myocardial infarction patients. Int J Clin Lab Res, 2000; 30: 179-85
35. Ding`YA, MacIntyre DE, Kenyon CJ, et al. Potentiation of adrenaline-induced platelet aggregation by angiotensin II. Thromb Haemost, 1985: 54: 717-20
36. Rakugi H, Jacob HJ, Krieger JE, et al. Vascular injury induces angiotensinogen gene expression in the media and neointima. Circulation, 1993; 87: 283-90
37. Samani NJ, Thompson JR, O`Toole L, et al. A meta-analysis of the association of the deletion allele of the angiotensin converting enzyme gene with myocardial infarction. Circulation, 1996; 94: 708-12
38. Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an angiotensin converting enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J med, 1995; 332: 706-11
39. Volzke H, Hertwig S, Rettig R, Motz W. The angiotensinogen gene 235T variant is associated with an increased risk of restenosis after percutaneous transluminal coronary angioplasty. Clin Sci (Lond), 2000; 99(1): 19-25
40. Hertwig S, Volzke H, Robinson DM, et al. Angiotensinogen M235T polymorphism and recurrent restenosis after repeated percutaneous transluminal coronary angioplasty. Clin Sci, 2002; 103: 101-6
41. Ribichini F, Ferrero V, Matullo G, et al. Association study of the I/D polymorphism and plasma angiotensin-converting enzyme (ACE) as risk factors for stent restenosis. Clin Sci (Lond), 2004; 107(4): 381-9
42. Ryu SK, Cho EY, Park HY, Im EK, et al. Renin-angiotensin-aldosterone system (RAAS) gene polymorphism as a risk factor of coronary in-stent restenosis. Yonsei Med J, 2002; 43(4): 461-72
43. Wijpkema JS, van Haelst PL, Monraats PS, et al. Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1. Pharmacogenet Genomics, 2006; 16(5): 331-7
44. Le Tourneau T, Van Belle E, Corseaux D, et al. Role of nitric oxide in restenosis after experimental balloon angioplasty in the hypercholesterolemic rabbit: effects on neointimal hyperplasia and vascular remodeling. JACC, 1999; 33: 876-82
45. Hibi K, Ishigami T, Tamura K, et al. endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension, 1998; 32: 521-6
46. Suzuki T, Okumura K, Sone T, et al. The Glu298Asp polymorphism in endothelial nitric oxide synthase gene is associated with coronary in-stent restenosis. Int J Cardiol, 2002; 6: 71-6
47. Chung SL, Chiou KR, Charng MJ. 677TT polymorphism of methylenetetrahydrofolate reductase in combination with low serum vitamin B (12) is associated with coronary in-stent restenosis. Catheter Cardiovasc Interv. 2006 67 (3): 349-55
48. Toshisuke Morita. Heme Oxygenase and Atherosclerosis. Arterioscler. Thromb Vasc Biol, 2005; 25: 1786 - 95
49. Exner M, Schillinger M, Minar E, et al. Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with restenosis after percutaneous transluminal angioplasty. J Endovasc Ther, 2001; 8: 433-40
50. Chen YH, Chau LY, Lin MW, et al. Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with angiographic restenosis after coronary stenting. Eur Heart J, 2004; 25: 39-47
51. Gulesserian T, Wenzel C, Endler G, et al. Clinical Restenosis after Coronary Stent Implantation Is Associated with the Heme Oxygenase-1 Gene Promoter Polymorphism and the Heme Oxygenase-1 -99G/C Variant. Clin Chem, 2005; 51, (9): 1661-5
52. Li P, Gomma MA, Palmen J, Hawe E, et al. The microsatellite polymorphism of heme oxygenase-1 is associated with baseline plasma IL-6 level but not with restenosis after coronary in-stenting. Chin Med J, 2005; 118(18): 1525 - 32
53. Shi Y, Niculescu К, Wang D, et al. Increased NAD (P) H Oxidase end Reactive Oxygen Species in Coronary Arteries After Balloon Injury. Arterioscler. Thromb. Vasc. Biol., 2001; 21: 739- 45
54. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett, 1991; 286: 152 - 4
55. Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphism of paraoxonase and the risk of coronary artery disease. Arterioscler Thromb Vasc Biol, 1997; 17: 1067 - 73
Рецензия
Для цитирования:
Шувалова Ю.А., Мешков А.Н., Каминный А.И., Пиксина Г.Ф., Кухарчук В.В. Патофизиологические механизмы и генетические маркеры рестеноза после чрескожных коронарных вмешательств. Кардиоваскулярная терапия и профилактика. 2007;6(5):107-114.
For citation:
Shuvalova Yu.A., Meshkov A.N., Kaminny A.I., Piksina G.F., Kukharchuk V.V. Restenosis pathophysiological mechanisms and genetic markers after percutaneous coronary interventions. Cardiovascular Therapy and Prevention. 2007;6(5):107-114. (In Russ.)
Просмотров:
587
ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)
ISSN 2619-0125 (Online)
Послать статью по эл. почте 
